Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

By M. Páez-Ribes, Elizabeth Allen, James Hudock, Takaaki Takeda, H. Okuyama, F. Viñals, M. Inoue, G. Bergers, D. Hanahan, O. Casanovas. Cancer Cell, 2009

2,440 citations recorded by the source corpus.

Subfields: Cancer Research, Cellular and Molecular Neuroscience, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/548e7f466d50d4b551529f242563ff56efc42636

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Cellular and Molecular Neuroscience

In Molecular Biology

Citations in the corpus

Hypoxia and hypoxia-inducible factors (HIFs): master regulators of metastasis (2010, background): “increased invasiveness and metastasis of tumor cells in preclinical models (55, 56), because these drugs induced”
Ten years of anti-vascular endothelial growth factor therapy (2016, background): “Studies in a transgenic model of PNET have indicated that treatment with anti-VEGFR2 antibodies or other VEGFA pathway inhibitors increases tumour invasiveness and metastasis, likely mediated by hypoxia, cMET upregulation and EMT 176 .”
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 (2009, background): “angiogenesis might, in the long run, induce angiogenesis as a rebound phenomenon and have been demonstrated in preclinical studies to induce tumour progression and metastases [17–19].”
Signal transduction by vascular endothelial growth factor receptors. (2012, background): “…therapies with resistance, rescue (Bergers and Hanahan 2008), and, at least in mouse models, increased invasion and metastasis (Ebos et al. 2009; Paez-Ribes et al. 2009) have shown that we need to learn more about how blood vessels contribute to and are affected by the metabolism of a given…”
Differential Macrophage Programming in the Tumor Microenvironment (2012, positive): “Although nutrient deprivation is the goal of anti-angiogenic therapy, the resulting hypoxia actually seems to promote malignant conversion and metastasis [112].”
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis (2011, background): “The first finding comes from two preclinical studies showing that the benefits from VEGF-pathway-inhibitor monotherapy can depend on disease stage and treatment circumstances and can, in certain settings, be offset by increased aggressive invasiveness and augmented metastatic potential”
Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. (2011, background): “However, antiangiogenic treatments targeting the VEGF pathway rarely induce durable tumor responses, both in mice and patients with cancer (Bergers and Hanahan, 2008), and may also favor metastasis in selected tumor models (Ebos et al., 2009; Paez-Ribes et al., 2009).”
Exciting New Advances in Neuro-Oncology (2010, background): “8 , 9 From a clinician’s standpoint, it is a simple fact that there will be heterogeneity of tumor response from one malignant glioma case to the next.”